Troponin in hematologic oncology

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In cardiology practice, the standard method of evaluating patients with suspected ischemic myocardial injury is an assay that measures the release of troponin into the bloodstream. In hematologic oncology practice, troponin has been investigated extensively as a measure of myocardial injury after therapy with radiation and anthracyclines and after myeloablative therapies with stem cell replacement. This review describes the current literature on use of troponin for monitoring early and late complications of systemic chemotherapy. The use of troponin to assess the value of cardioprotective agents (used for prevention of chemotherapy-induced myocardial injury) also is reviewed. Because a number of nonmalignant hematologic disorders such as hypereosinophilic syndrome, thrombotic thrombocytopenic purpura, and immunoglobulin light-chain amyloidosis can affect the heart, the use of the troponin in assessing these patients' prognoses is also covered.

Original languageEnglish (US)
Pages (from-to)194-203
Number of pages10
JournalLeukemia and Lymphoma
Volume49
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Troponin
Wounds and Injuries
Hypereosinophilic Syndrome
Cardiotonic Agents
Immunoglobulin Light Chains
Thrombotic Thrombocytopenic Purpura
Drug Therapy
Anthracyclines
Amyloidosis
Cardiology
Radiotherapy
Stem Cells

Keywords

  • Amyloidosis
  • Anthracycline
  • Cardiomyopathy
  • Doxorubicin
  • Troponin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Troponin in hematologic oncology. / Gertz, Morie.

In: Leukemia and Lymphoma, Vol. 49, No. 2, 01.02.2008, p. 194-203.

Research output: Contribution to journalReview article

Gertz, Morie. / Troponin in hematologic oncology. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 2. pp. 194-203.
@article{c2ddc471d0374170abf97bb055ef3ef6,
title = "Troponin in hematologic oncology",
abstract = "In cardiology practice, the standard method of evaluating patients with suspected ischemic myocardial injury is an assay that measures the release of troponin into the bloodstream. In hematologic oncology practice, troponin has been investigated extensively as a measure of myocardial injury after therapy with radiation and anthracyclines and after myeloablative therapies with stem cell replacement. This review describes the current literature on use of troponin for monitoring early and late complications of systemic chemotherapy. The use of troponin to assess the value of cardioprotective agents (used for prevention of chemotherapy-induced myocardial injury) also is reviewed. Because a number of nonmalignant hematologic disorders such as hypereosinophilic syndrome, thrombotic thrombocytopenic purpura, and immunoglobulin light-chain amyloidosis can affect the heart, the use of the troponin in assessing these patients' prognoses is also covered.",
keywords = "Amyloidosis, Anthracycline, Cardiomyopathy, Doxorubicin, Troponin",
author = "Morie Gertz",
year = "2008",
month = "2",
day = "1",
doi = "10.1080/10428190701813026",
language = "English (US)",
volume = "49",
pages = "194--203",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Troponin in hematologic oncology

AU - Gertz, Morie

PY - 2008/2/1

Y1 - 2008/2/1

N2 - In cardiology practice, the standard method of evaluating patients with suspected ischemic myocardial injury is an assay that measures the release of troponin into the bloodstream. In hematologic oncology practice, troponin has been investigated extensively as a measure of myocardial injury after therapy with radiation and anthracyclines and after myeloablative therapies with stem cell replacement. This review describes the current literature on use of troponin for monitoring early and late complications of systemic chemotherapy. The use of troponin to assess the value of cardioprotective agents (used for prevention of chemotherapy-induced myocardial injury) also is reviewed. Because a number of nonmalignant hematologic disorders such as hypereosinophilic syndrome, thrombotic thrombocytopenic purpura, and immunoglobulin light-chain amyloidosis can affect the heart, the use of the troponin in assessing these patients' prognoses is also covered.

AB - In cardiology practice, the standard method of evaluating patients with suspected ischemic myocardial injury is an assay that measures the release of troponin into the bloodstream. In hematologic oncology practice, troponin has been investigated extensively as a measure of myocardial injury after therapy with radiation and anthracyclines and after myeloablative therapies with stem cell replacement. This review describes the current literature on use of troponin for monitoring early and late complications of systemic chemotherapy. The use of troponin to assess the value of cardioprotective agents (used for prevention of chemotherapy-induced myocardial injury) also is reviewed. Because a number of nonmalignant hematologic disorders such as hypereosinophilic syndrome, thrombotic thrombocytopenic purpura, and immunoglobulin light-chain amyloidosis can affect the heart, the use of the troponin in assessing these patients' prognoses is also covered.

KW - Amyloidosis

KW - Anthracycline

KW - Cardiomyopathy

KW - Doxorubicin

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=38849127394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849127394&partnerID=8YFLogxK

U2 - 10.1080/10428190701813026

DO - 10.1080/10428190701813026

M3 - Review article

C2 - 18231905

AN - SCOPUS:38849127394

VL - 49

SP - 194

EP - 203

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -